Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PYY 3-36 nasal spray is a synthetic formulation of the human gut hormone peptide YY (fragment 3–36), delivered via the intranasal route. Peptide YY (PYY) is a naturally occurring hormone released postprandially from L-cells in the gastrointestinal tract and acts as a physiological inhibitor of food intake by promoting satiety. The mechanism of action involves agonism at neuropeptide Y receptor type 2 (Y2R), primarily in the hypothalamic arcuate nucleus, leading to reduced neuropeptide Y release and appetite suppression. The drug was developed as a non-invasive treatment for obesity, aiming to reduce body weight by decreasing caloric intake through enhanced satiety signaling[1][2][4]. Clinical trials have shown that while intranasal administration is generally safe and well-tolerated at lower doses, higher doses are associated with significant nausea and vomiting. Efficacy data indicate that this formulation did not achieve clinically meaningful weight loss compared to placebo over periods up to 24 weeks[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PYY 3-36 nasal spray.